Stephen H Rappaport
Overview
Explore the profile of Stephen H Rappaport including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
12
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singer S, Betthauser K, Barber A, Bookstaver Korona R, Dixit D, Groth C, et al.
Hosp Pharm
. 2024 Nov;
59(6):650-659.
PMID: 39493571
Critical care pharmacists complete comprehensive medication reviews in Post Intensive Care Syndrome (PICS) patients at Intensive Care Unit Recovery Centers (ICU-RCs) to optimize medication therapies after hospital discharge. Inpatient pharmacists...
2.
Beaudrie-Nunn A, Poyant J, Groth C, Rappaport S, Kruer R, Miller E, et al.
Am J Health Syst Pharm
. 2024 Aug;
82(5):e262-e273.
PMID: 39162570
Purpose: To compare the incidence of ICU pharmacist interventions in intensive care unit recovery center (ICU-RC) in-person and virtual clinic visits. Methods: This was a post hoc analysis of interventions...
3.
Vanini D, Corvelli J, Maynard K, Rappaport S, Grasso G, Jones R, et al.
Crit Care Explor
. 2024 Mar;
6(3):e1062.
PMID: 38481543
Importance: Buprenorphine for opioid use disorder (OUD) is commonly used in the outpatient setting with increasing use in hospitalized patients. However, there is limited literature describing its use in critically...
4.
Stollings J, Poyant J, Groth C, Rappaport S, Kruer R, Miller E, et al.
J Intensive Care Med
. 2023 May;
38(10):957-965.
PMID: 37198935
Background: Post-intensive care syndrome (PICS) is defined as a new or worsening impairment in physical, cognitive, or mental health following critical illness. Intensive care unit recovery centers (ICU-RC) are one...
5.
Young M, Rappaport S, Belz S, Kaufman D, Haas C
Ann Pharmacother
. 2023 Apr;
58(1):37-43.
PMID: 37042295
Background: The optimal loading dose of digoxin in patients with reduced kidney function is unknown. Tertiary references recommend reduced loading doses; however, these recommendations are based on immunoassays that are...
6.
Rappaport S, Vineyard T, Hack M, Shah T, Dooley J
Am J Health Syst Pharm
. 2022 Dec;
80(7):430-434.
PMID: 36566498
Purpose: Medication use may affect imaging results. In this case study, we report a case of lanthanum ingestion resulting in imaging consistent with ingested metallic foreign bodies. Summary: Hyperphosphatemia affects...
7.
Rappaport S, Clark J, Delibert S, Maynard K, Prasad P, Kaufman D, et al.
Am J Respir Crit Care Med
. 2020 Sep;
202(12):1731-1733.
PMID: 32931713
No abstract available.
8.
Minhaj F, Rappaport S, Foster J, Gashlin L
J Patient Saf
. 2020 Jun;
17(8):e1585-e1588.
PMID: 32502115
Objective: Opioids are high-risk medications in the inpatient setting because of their potential for significant patient harm. The primary objective was to identify risk factors that predispose inpatients to develop...
9.
Rappaport S, Endicott J, Gilbert M, Farkas J, Clouser R, McMillian W
J Endocr Soc
. 2019 May;
3(5):1079-1086.
PMID: 31069278
Background: Insulin via continuous intravenous infusion (ICII) is a standard of care for treating patients with diabetic ketoacidosis (DKA). Once DKA is resolved, ICII is transitioned to subcutaneous therapy. However,...